Peter Forsberg, Co-Director Plasma Cell Disorders Program at Colorado Blood Cancer Institute Medical Group shared a post on LinkedIn:
“Multiple myeloma is a rare and often misunderstood blood cancer that affects plasma cells in the bone marrow.
Over the past decade, we have seen meaningful shifts in its treatment landscape. Advances in CAR T-cell therapy, bispecific antibodies, and novel combinations are changing how we think about sequencing, durability of response, and long-term disease management.
At Colorado Blood Cancer Institute Medical Group Institute, we are actively engaged in clinical research that evaluates emerging therapies across lines of treatment.
Through my role as an Executive Member of the Myeloma Research Executive Committee within Sarah Cannon Research Institute, I collaborate with investigators nationally to help advance studies that will help define our next generation of care.
Multiple Myeloma Awareness Month is a reminder that sustained progress in myeloma depends on rigorous research, strong partnerships, and a continued commitment to advancing evidence-based innovation.”
Other articles about Multiple Myeloma on OncoDaily.